Abstract Body

Of new HIV diagnoses among US youth, 81% occur among young men who have sex with men (YMSM). Using data from Adolescent Trials Network (ATN) studies 110/113 of high-risk US YMSM ages 15-22, we examined the clinical impact, cost, and cost-effectiveness of 4 HIV screening strategies for high-risk YMSM starting at age 15.

We simulated a cohort of high-risk HIV-uninfected 14-year-old MSM in the US who faced age-specific risks of HIV infection (0.91-6.41/100,000PY, peak incidence ages 15-18) based on ATN 110/113 (observational; incident infections despite PrEP adherence of 34-56%). We modeled HIV screening ($36/test) every 3 years, annually, biannually, and quarterly beginning at age 15, each in addition to current US screening practices for YMSM (16-53% screened at least once by ages 15-22). We used published YMSM HIV care continuum data, including screen acceptance (80%), linkage-to-care/antiretroviral therapy (ART) initiation (76%), disease progression, and HIV care costs. Outcomes included CD4 count at diagnosis, the HIV care continuum (proportions HIV-diagnosed, linked to care, retained in care, and virologically suppressed), one generation of secondary HIV transmissions, life expectancy, lifetime costs, and incremental cost-effectiveness ratios (ICER) in $/year-of-life saved (YLS) from the healthcare system perspective. In sensitivity analyses, we varied HIV incidence, screening and linkage rates, and costs.

All screening strategies beginning at age 15 diagnosed greater proportions of lifetime infections compared to current practice alone (81-99% vs. 35%). Compared to the next most effective strategy, quarterly screening beginning at age 15 was cost-effective ($84,000/YLS) by US standards (<$100,000/YLS) (Table). Including just first-generation HIV transmissions averted, the ICER was markedly lower ($20,900/YLS). These results were most sensitive to current HIV screening practice rates and linkage-to-care/ART initiation. If HIV incidence peaked at older ages, an older starting age for HIV screening had more favorable cost-effectiveness outcomes; if absolute HIV incidence was lower, less frequent screening was more favorable.

For high-risk US YMSM, quarterly HIV screening beginning at age 15, compared to less frequent screening beginning at age 15, would improve clinical outcomes and be cost-effective. To optimize clinical outcomes, screening should begin at or after the peak of population-specific HIV incidence.